In immunotherapy for prostate cancer, cytotoxic T lymphocyte-associated antigen 4 (CTLA4), programmed death ligand-1 (PD-L1), and programmed death-1 (PD-1) inhibitors have shown promising outcomes in terms of anti-tumor immune therapy. The gene discussed is CTLA4; the disease is neoplasm.